Engineered bioresponsive nanotherapeutics: recent advances in the treatment of atherosclerosis and ischemic-related disease. Issue 24 (4th June 2021)

• Record Type: Journal Article
• Authors: Rumanti, Ayu Pratiwi; Maruf, Ali; Liu, Huawen; Ge, Shuping; Lei, Daoxi; Wang, Guixue
• Is Part Of: Journal of materials chemistry. Volume 9:Issue 24(2021)
• Page Start: 4804
• Page End: 4825
• Publication Date: 2021-06-04
• Subjects: Materials -- Periodicals; Chemistry, Analytic -- Periodicals; Biomedical materials -- Research -- Periodicals; 543.0284
• DOI: 10.1039/d1tb00330e
• Languages: English
• ISSNs: 2050-750X

Abstract

Abstract : Bioresponsive nanotherapeutics are promising candidates as diagnostic and therapeutic agents against atherosclerosis and ischemic-related diseases. Abstract : Biological stimuli that are present during the pathogenesis of disease have gained considerable interest as a critical element for the design of smart drug delivery systems. Recently, the utilization of biological stimuli-responsive (bioresponsive) nanotheranostic agents to treat atherosclerosis and ischemic-related diseases has demonstrated significant outcomes in preclinical studies. Those diseases share similar hallmarks, including high levels of endogenous reactive oxygen species (ROS), low pH, and high enzyme activity. Interestingly, other relevant biological stimuli such as shear stress, cholesterol, and glutathione have recently been explored as internal stimuli to trigger drug release and some particular actions. In addition, a number of strategies can be proposed to enhance their targeting efficiency, diagnostic properties, and efficacy rate. This review discusses recent advancements in the preclinical studies of bioresponsive nanotherapeutics as diagnostic and therapeutic agents against atherosclerosis and ischemic-related diseases as well as some potential strategies to overcome the current limitations.